Pub Date : 2026-01-02DOI: 10.1001/jamaophthalmol.2025.5492
Shabnam Raji, Robert Edward MacLaren, Peter Charbel Issa, Jasmina Cehajic-Kapetanovic
Importance: Recent insights into impaired glutamylation caused by distal truncating variants in RPGR ORF15 and its association with the cone-dominated phenotype have provided the first molecular evidence of a genotype-phenotype correlation in male individuals with X-linked RPGR-related retinal dystrophy, though this correlation remains unexplored in female carriers.
Objective: To characterize the clinical phenotype in female carriers of RPGR variants causing X-linked cone dystrophy in hemizygous male individuals.
Design, setting, and participants: This case-control study was conducted at a specialist genetics clinic from May to December 2024. A total of 11 patients were examined, including female carriers with RPGR variants causing cone dystrophy (n = 7) and age-similar female carriers of RPGR variants causing rod-cone dystrophy as controls (n = 4).
Exposures: RPGR variants associated with X-linked cone dystrophy in hemizygous male individuals.
Main outcomes and measures: Results of ophthalmic examination, multimodal retinal imaging, and functional testing.
Results: Seven female carriers aged 11 to 71 years were identified from RPGR cone dystrophy pedigrees. Visual acuity ranged from 6/4.8 to 6/7.5 (Snellen, 20/16 to 20/25), and 4 of the 7 participants experienced photophobia. Myopia and high cylindrical powers were common (6/7 [86%]), with myopia greater than -6.00 D in 2 patients. Fundus autofluorescence imaging revealed a diffuse, granular hyperautofluorescence pattern limited to the posterior pole, compared with the typical spoke pattern that extended into the far periphery in female carriers from RPGR rod-cone pedigrees. Green reflectance imaging most sensitively detected an abnormality in the form of an en face tapetallike sheen, which colocalized with a hyperreflective outer retinal band observed on optical coherence tomography. Ultra-widefield retinal imaging demonstrated no peripheral abnormalities. A mosaic pattern of reduced retinal sensitivity was found within the central 20° on microperimetry, which did not correlate with features observed on retinal imaging. Normal rod responses were measured on electroretinography, but average cone responses were 60.1% of the lower normal limit compared with 36% in male probands.
Conclusions and relevance: This study identified a distinct phenotype in female carriers of RPGR variants causing X-linked cone dystrophy. In this cohort, the phenotype was consistent with mild cone dysfunction and anatomical macular changes. Depending on X-inactivation skew and rate of disease progression, some female carriers may be suitable for emerging gene therapies currently in clinical trials for affected male individuals.
{"title":"Phenotypic Manifestations in Female Carriers of RPGR ORF15 Variants Causing X-Linked Cone Dystrophy.","authors":"Shabnam Raji, Robert Edward MacLaren, Peter Charbel Issa, Jasmina Cehajic-Kapetanovic","doi":"10.1001/jamaophthalmol.2025.5492","DOIUrl":"10.1001/jamaophthalmol.2025.5492","url":null,"abstract":"<p><strong>Importance: </strong>Recent insights into impaired glutamylation caused by distal truncating variants in RPGR ORF15 and its association with the cone-dominated phenotype have provided the first molecular evidence of a genotype-phenotype correlation in male individuals with X-linked RPGR-related retinal dystrophy, though this correlation remains unexplored in female carriers.</p><p><strong>Objective: </strong>To characterize the clinical phenotype in female carriers of RPGR variants causing X-linked cone dystrophy in hemizygous male individuals.</p><p><strong>Design, setting, and participants: </strong>This case-control study was conducted at a specialist genetics clinic from May to December 2024. A total of 11 patients were examined, including female carriers with RPGR variants causing cone dystrophy (n = 7) and age-similar female carriers of RPGR variants causing rod-cone dystrophy as controls (n = 4).</p><p><strong>Exposures: </strong>RPGR variants associated with X-linked cone dystrophy in hemizygous male individuals.</p><p><strong>Main outcomes and measures: </strong>Results of ophthalmic examination, multimodal retinal imaging, and functional testing.</p><p><strong>Results: </strong>Seven female carriers aged 11 to 71 years were identified from RPGR cone dystrophy pedigrees. Visual acuity ranged from 6/4.8 to 6/7.5 (Snellen, 20/16 to 20/25), and 4 of the 7 participants experienced photophobia. Myopia and high cylindrical powers were common (6/7 [86%]), with myopia greater than -6.00 D in 2 patients. Fundus autofluorescence imaging revealed a diffuse, granular hyperautofluorescence pattern limited to the posterior pole, compared with the typical spoke pattern that extended into the far periphery in female carriers from RPGR rod-cone pedigrees. Green reflectance imaging most sensitively detected an abnormality in the form of an en face tapetallike sheen, which colocalized with a hyperreflective outer retinal band observed on optical coherence tomography. Ultra-widefield retinal imaging demonstrated no peripheral abnormalities. A mosaic pattern of reduced retinal sensitivity was found within the central 20° on microperimetry, which did not correlate with features observed on retinal imaging. Normal rod responses were measured on electroretinography, but average cone responses were 60.1% of the lower normal limit compared with 36% in male probands.</p><p><strong>Conclusions and relevance: </strong>This study identified a distinct phenotype in female carriers of RPGR variants causing X-linked cone dystrophy. In this cohort, the phenotype was consistent with mild cone dysfunction and anatomical macular changes. Depending on X-inactivation skew and rate of disease progression, some female carriers may be suitable for emerging gene therapies currently in clinical trials for affected male individuals.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12761763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamaophthalmol.2025.6124
{"title":"Error in Open Access Status and in Results.","authors":"","doi":"10.1001/jamaophthalmol.2025.6124","DOIUrl":"10.1001/jamaophthalmol.2025.6124","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"144 1","pages":"114"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12809361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamaophthalmol.2025.4652
Anokhi S Kholwadwala, Andrew G Lee
{"title":"Prediction of Optic Disc Edema Progression in Spaceflight.","authors":"Anokhi S Kholwadwala, Andrew G Lee","doi":"10.1001/jamaophthalmol.2025.4652","DOIUrl":"10.1001/jamaophthalmol.2025.4652","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"40-41"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamaophthalmol.2025.4370
Sobha Sivaprasad
{"title":"Retinal Sensitivity in Areas of Retinal Nonperfusion.","authors":"Sobha Sivaprasad","doi":"10.1001/jamaophthalmol.2025.4370","DOIUrl":"10.1001/jamaophthalmol.2025.4370","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"98"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1001/jamaophthalmol.2025.5103
Emily S Wong,Richard W Choy,Yuzhou Zhang,Hin Yin Chan,Li Jia Chen,Chi Pui Pang,Clement C Tham,Jason C Yam
ImportanceRetinopathy of prematurity (ROP) is a leading cause of childhood blindness, particularly in low- and middle-income countries. With advancements in neonatal care, a projected rising trend and burden of ROP-related vision loss necessitates attention.ObjectiveTo analyze global trends in ROP-related visual impairment from 1990 to 2021 and identify risk factors for increased prevalence of visual loss.Design, Setting, and ParticipantsThis cross-sectional study used the Global Burden of Disease 2021 dataset to identify ROP-related visual outcomes across 204 countries from 1990 to 2021. Socioeconomic and health care indicators were incorporated to identify risk factors for increased prevalence of visual loss, and machine-learning models were used for outcome forecasting until 2050. This analysis was conducted between January 1 and March 30, 2025.ExposurePremature birth.Main Outcome and MeasuresThe main outcome was global prevalence of ROP-related visual impairment, stratified by severity of visual impairment and the associated factors.ResultsA total of 8.79 million cases of ROP-related visual loss were documented between 1990 and 2021 (4.57 million male and 4.22 million female patients), and the number of cases globally remained stable during this time. Countries with a low social demographic index (SDI) (536 899 cases; 95% uncertainty interval [UI], 418 860-655 140 cases) and low-middle SDI (802 078 cases; 95% UI, 590 539-1 032 465 cases) accounted for the majority of ROP-related visual loss cases in 2021. Despite a sharp decline since the 2000s, prevalence of ROP-related blindness remains disproportionately high in low and low-middle SDI countries. The prevalence pattern shows a shifting burden of ROP-related visual impairment, with high-middle SDI countries in particular experiencing an increasing prevalence rate in all-grade visual loss related to ROP. Multivariable regression analysis found that a lower primary completion rate (estimate, -2.33 [95% CI, -3.11 to 1.55] cases per 100 000 people), higher out-of-pocket health care expense (estimate, 2.61 [95% CI, 1.86 to 3.35] cases per 100 000 people), lower social insurance coverage (estimate, -2.79 [95% CI, -3.76 to 1.82] cases per 100 000 people), lower prenatal screening coverage (estimate, -3.91 [95% CI, -4.63 to 3.19] cases per 100 000 people) and nursing staff density (estimate, -2.07 [95% CI, -3.03 to 1.11] cases per 100 000 people) were associated with higher visual loss prevalence. Projections indicate that without targeted interventions, the burden of ROP-related visual impairment will continue to escalate, particularly in high-middle and middle SDI regions.Conclusions and RelevanceThis cross-sectional study found that persistent disparities in ROP-related visual loss burden remain between socioeconomic contexts and SDI groups, especially in terms of ROP-related blindness. Addressing socioeconomic disparities, enhancing neonatal care access, and implementing universal ROP screening
{"title":"Global and Regional Trends in Retinopathy of Prematurity.","authors":"Emily S Wong,Richard W Choy,Yuzhou Zhang,Hin Yin Chan,Li Jia Chen,Chi Pui Pang,Clement C Tham,Jason C Yam","doi":"10.1001/jamaophthalmol.2025.5103","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5103","url":null,"abstract":"ImportanceRetinopathy of prematurity (ROP) is a leading cause of childhood blindness, particularly in low- and middle-income countries. With advancements in neonatal care, a projected rising trend and burden of ROP-related vision loss necessitates attention.ObjectiveTo analyze global trends in ROP-related visual impairment from 1990 to 2021 and identify risk factors for increased prevalence of visual loss.Design, Setting, and ParticipantsThis cross-sectional study used the Global Burden of Disease 2021 dataset to identify ROP-related visual outcomes across 204 countries from 1990 to 2021. Socioeconomic and health care indicators were incorporated to identify risk factors for increased prevalence of visual loss, and machine-learning models were used for outcome forecasting until 2050. This analysis was conducted between January 1 and March 30, 2025.ExposurePremature birth.Main Outcome and MeasuresThe main outcome was global prevalence of ROP-related visual impairment, stratified by severity of visual impairment and the associated factors.ResultsA total of 8.79 million cases of ROP-related visual loss were documented between 1990 and 2021 (4.57 million male and 4.22 million female patients), and the number of cases globally remained stable during this time. Countries with a low social demographic index (SDI) (536 899 cases; 95% uncertainty interval [UI], 418 860-655 140 cases) and low-middle SDI (802 078 cases; 95% UI, 590 539-1 032 465 cases) accounted for the majority of ROP-related visual loss cases in 2021. Despite a sharp decline since the 2000s, prevalence of ROP-related blindness remains disproportionately high in low and low-middle SDI countries. The prevalence pattern shows a shifting burden of ROP-related visual impairment, with high-middle SDI countries in particular experiencing an increasing prevalence rate in all-grade visual loss related to ROP. Multivariable regression analysis found that a lower primary completion rate (estimate, -2.33 [95% CI, -3.11 to 1.55] cases per 100 000 people), higher out-of-pocket health care expense (estimate, 2.61 [95% CI, 1.86 to 3.35] cases per 100 000 people), lower social insurance coverage (estimate, -2.79 [95% CI, -3.76 to 1.82] cases per 100 000 people), lower prenatal screening coverage (estimate, -3.91 [95% CI, -4.63 to 3.19] cases per 100 000 people) and nursing staff density (estimate, -2.07 [95% CI, -3.03 to 1.11] cases per 100 000 people) were associated with higher visual loss prevalence. Projections indicate that without targeted interventions, the burden of ROP-related visual impairment will continue to escalate, particularly in high-middle and middle SDI regions.Conclusions and RelevanceThis cross-sectional study found that persistent disparities in ROP-related visual loss burden remain between socioeconomic contexts and SDI groups, especially in terms of ROP-related blindness. Addressing socioeconomic disparities, enhancing neonatal care access, and implementing universal ROP screening ","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"46 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145830437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1001/jamaophthalmol.2025.5515
Thanitsara Rittiphairoj
{"title":"The Global Epidemiologic Transition of Retinopathy of Prematurity: Interpreting Forecasts Through a Health-System Lens.","authors":"Thanitsara Rittiphairoj","doi":"10.1001/jamaophthalmol.2025.5515","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5515","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"19 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145830440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.1001/jamaophthalmol.2025.5098
Won Ki Lee,Tien Y Wong,Shih-Jen Chen,Xiaodong Sun,Chui Ming Gemmy Cheung,Rufino Silva,Federico Ricci,Xin Zhang,Tobias Machewitz,Andrea Schulze,Ursula M Schmidt-Ott,Min Zhao,Zoran Hasanbasic,Sergio Leal,Tomohira Iida,
ImportanceIn the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated noninferior (4-letter margin) best-corrected visual acuity (BCVA) gains vs aflibercept, 2 mg, in participants with neovascular age-related macular degeneration (nAMD). This post hoc subgroup analysis evaluated clinical outcomes in participants with polypoidal choroidal vasculopathy (PCV).ObjectiveTo compare the efficacy and safety of aflibercept, 8 mg vs 2 mg, monotherapy among participants with PCV in the PULSAR trial.Design, Setting, and ParticipantsThis was a post hoc subgroup analysis of the PULSAR randomized clinical trial. The setting included hospitals and clinics in 12 countries where indocyanine green angiography (ICGA) was performed to identify PCV. Included were a subgroup of adults with nAMD enrolled in the PULSAR trial with ICGA-confirmed PCV. Study data were analyzed from August 2020 to July 2022.InterventionsParticipants were randomly assigned 1:1:1 to aflibercept, 8 mg, every 12 weeks or 16 weeks, or aflibercept, 2 mg, every 8 weeks, each after 3 initial monthly doses. From week 16, dosing intervals in the treatment arms receiving 8 mg every 12 weeks and every 16 weeks were shortened if predefined disease activity criteria were met at prespecified visits.Main Outcomes and MeasuresLeast-squares (LS) mean change in BCVA from baseline at week 48.ResultsA total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, -4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; -0.7; 95% CI, -4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48.Conclusions and RelevanceResults of this post hoc analysis of the PULSAR randomized clinical trial in participants with PCV demonstrated simila
{"title":"Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.","authors":"Won Ki Lee,Tien Y Wong,Shih-Jen Chen,Xiaodong Sun,Chui Ming Gemmy Cheung,Rufino Silva,Federico Ricci,Xin Zhang,Tobias Machewitz,Andrea Schulze,Ursula M Schmidt-Ott,Min Zhao,Zoran Hasanbasic,Sergio Leal,Tomohira Iida, ","doi":"10.1001/jamaophthalmol.2025.5098","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5098","url":null,"abstract":"ImportanceIn the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated noninferior (4-letter margin) best-corrected visual acuity (BCVA) gains vs aflibercept, 2 mg, in participants with neovascular age-related macular degeneration (nAMD). This post hoc subgroup analysis evaluated clinical outcomes in participants with polypoidal choroidal vasculopathy (PCV).ObjectiveTo compare the efficacy and safety of aflibercept, 8 mg vs 2 mg, monotherapy among participants with PCV in the PULSAR trial.Design, Setting, and ParticipantsThis was a post hoc subgroup analysis of the PULSAR randomized clinical trial. The setting included hospitals and clinics in 12 countries where indocyanine green angiography (ICGA) was performed to identify PCV. Included were a subgroup of adults with nAMD enrolled in the PULSAR trial with ICGA-confirmed PCV. Study data were analyzed from August 2020 to July 2022.InterventionsParticipants were randomly assigned 1:1:1 to aflibercept, 8 mg, every 12 weeks or 16 weeks, or aflibercept, 2 mg, every 8 weeks, each after 3 initial monthly doses. From week 16, dosing intervals in the treatment arms receiving 8 mg every 12 weeks and every 16 weeks were shortened if predefined disease activity criteria were met at prespecified visits.Main Outcomes and MeasuresLeast-squares (LS) mean change in BCVA from baseline at week 48.ResultsA total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, -4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; -0.7; 95% CI, -4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48.Conclusions and RelevanceResults of this post hoc analysis of the PULSAR randomized clinical trial in participants with PCV demonstrated simila","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"153 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145771384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号